BC Week In Review | Dec 21, 2018
Company News

Gilead expands immuno-oncology pipeline with license from Agenus

Gilead Sciences Inc. (NASDAQ:GILD) received rights to a bispecific immuno-oncology molecule and options for two additional immuno-oncology candidates from Agenus Inc. (NASDAQ:AGEN). Gilead received exclusive, worldwide rights to AGEN1423, options to bispecific antibody AGEN1223 and...
BC Extra | Dec 21, 2018
Company News

Gilead expands immuno-oncology pipeline with license from Agenus

Gilead Sciences Inc. (NASDAQ:GILD) received rights to a bispecific immuno-oncology molecule and options for two additional immuno-oncology candidates from Agenus Inc. (NASDAQ:AGEN). The deal, Gilead's second of the week, will also extend Agenus’ cash reserves....
Items per page:
1 - 2 of 2